Deutsche Bank AG Has $748,000 Position in Novavax, Inc. $NVAX

Deutsche Bank AG lowered its position in Novavax, Inc. (NASDAQ:NVAX) by 5.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 116,717 shares of the biopharmaceutical company’s stock after selling 6,864 shares during the quarter. Deutsche Bank AG owned approximately 0.07% of Novavax worth $748,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in NVAX. GF Fund Management CO. LTD. acquired a new stake in Novavax in the fourth quarter valued at $27,000. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Novavax in the first quarter valued at $71,000. GAMMA Investing LLC lifted its stake in Novavax by 2,272.5% in the first quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 11,340 shares during the last quarter. Kitching Partners LLC acquired a new stake in Novavax in the fourth quarter valued at $89,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Novavax in the first quarter valued at $99,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. B. Riley reissued a “buy” rating on shares of Novavax in a research report on Monday, May 19th. JPMorgan Chase & Co. dropped their price objective on shares of Novavax from $9.00 to $7.00 and set an “underweight” rating on the stock in a research report on Friday, May 9th. Citigroup assumed coverage on shares of Novavax in a research report on Tuesday, June 17th. They issued a “sell” rating and a $6.00 price objective on the stock. Finally, Bank of America reissued an “underperform” rating and issued a $7.00 price objective (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $15.57.

Novavax Price Performance

NASDAQ:NVAX opened at $7.52 on Tuesday. Novavax, Inc. has a 52 week low of $5.01 and a 52 week high of $15.22. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of 3.30, a P/E/G ratio of 0.10 and a beta of 2.50. The firm’s 50-day simple moving average is $7.31 and its 200 day simple moving average is $7.17. The company has a debt-to-equity ratio of 5.93, a quick ratio of 2.34 and a current ratio of 2.36.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.69. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The business had revenue of $239.24 million for the quarter, compared to analyst estimates of $149.19 million. During the same period last year, the firm earned $0.99 earnings per share. Novavax’s revenue for the quarter was down 42.4% compared to the same quarter last year. As a group, sell-side analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.